Introduction
Life sciences companies entering the UK market navigate two parallel clearance processes that must both be completed before commercial launch: MHRA regulatory approval and patent FTO. These are frequently managed sequentially — regulatory approval first, patent questions second. That sequencing creates the scenario that is most commercially damaging in life sciences IP: a product that has received MHRA approval after years of clinical and regulatory investment, only to face a patent infringement claim from an originator or other patent holder who has been watching the MHRA approval progress while their patent remains active.
MHRA approval gives a life sciences product the right to be sold in the UK. Patent FTO gives it the right to be sold without infringing a competitor’s patent. The two clearances are independent determinations — MHRA reviewers do not consider the patent landscape, and UKIPO does not consider MHRA approval status. Managing them in parallel, with FTO checkpoints aligned to MHRA approval milestones, is the approach that avoids the post-approval patent risk that sequential management creates.
The UK’s post-Brexit patent landscape adds a specific dimension to this for life sciences companies. As our analysis of how AI and software patent assessment changed in the UK after Aerotel covers, the UKIPO has been developing its own post-Brexit examination approach that diverges from EPO practice in specific ways. For life sciences FTO, the more immediate post-Brexit consideration is the UK’s independent SPC system — which diverged from the EU SPC Regulation after 2021 and must now be assessed separately from EU SPCs. This article covers the MHRA pathway structure, how FTO should be sequenced around MHRA milestones, and the patent categories specific to UK life sciences FTO.
The MHRA Regulatory Pathway: A Brief Overview for IP Teams
The three primary MHRA approval routes: Life sciences products enter the UK market through one of three primary MHRA regulatory routes. The National Procedure (NP) is a UK-only submission for products seeking marketing authorisation exclusively in Great Britain (England, Scotland, Wales). The Recognition Procedure (RP) allows UK applicants to use a marketing authorisation already granted by a recognised regulatory partner (EMA, FDA, Health Canada, TGA, or others) as the basis for a MHRA application, with a streamlined review against the approved dossier. The International Recognition Procedure (IRP) extends the same principle to a broader set of international regulatory decisions. Each route has a different timeline — NP reviews target 150 days for standard applications and 150 days with clock stops for major objections; RP and IRP reviews are compressed relative to NP where a recognised foreign approval exists.
MHRA’s Innovative Licensing and Access Pathway (ILAP): ILAP is MHRA’s accelerated pathway for innovative medicines that address unmet medical need. It combines early engagement with MHRA, targeted engagement with NICE and SMC for health technology assessment, and an Innovative Licensing and Access Pathway designation that provides a structured development and review timeline. For products receiving ILAP designation, the MHRA review timeline can be materially compressed relative to standard NP review. This compression — while commercially advantageous from a market access perspective — reduces the post-submission window available for FTO monitoring, making pre-submission FTO more critical.
The post-Brexit UK SPC system: Since the UK’s withdrawal from the EU, UK SPCs are granted under UK national law rather than the EU SPC Regulation. UK SPCs must be applied for separately from EU SPCs, are governed by the UK Patents Act and the UK SPC Regulations, and are assessed against the UK marketing authorisation rather than the EU marketing authorisation. For life sciences companies holding or facing SPCs in the UK market, the post-Brexit SPC system means that UK and EU SPC positions must be assessed separately — an EU SPC does not confer any protection in the UK, and vice versa.
MHRA TIMELINE NOTE: MHRA has been working to reduce review timelines since its independence from EMA post-Brexit. Standard NP applications have seen review times compress from 210+ days to closer to 150 days for straightforward applications. For life sciences IP teams, this compression means the post-submission patent risk window is shorter than it was in the EMA era — making pre-submission FTO more important and post-submission monitoring more time-sensitive.
Why MHRA Approval and Patent Clearance Are Not the Same
Regulatory approval grants market access, not freedom to operate: MHRA approval is a regulatory determination that a medicinal product is safe, effective, and of acceptable quality for its intended use under UK law. It does not involve any assessment of third-party patent positions. MHRA reviewers are not patent examiners and do not consider whether the product infringes patents held by originators or other IP holders. A product can receive full MHRA marketing authorisation and still be blocked from commercial sale by a patent infringement injunction on its first day in market. The regulatory clearance and the patent clearance are independent determinations that require separate processes.
The post-Brexit UK patent landscape: Brexit created a UK patent landscape that is distinct from the EU in several commercially significant ways for life sciences FTO. European patents validated in the UK before Brexit remain valid as UK national patents. New European patents granted by the EPO are validated in the UK through the UKIPO national phase process. The UK is not part of the UPC — all UK patent enforcement is through UK national courts, primarily the UK Intellectual Property Enterprise Court (IPEC) and the Business and Property Courts. UK SPCs are assessed under UK national law. For life sciences companies whose pre-Brexit FTO covered both EU and UK markets through a single European patent analysis, the post-Brexit UK market requires a separate national UK patent and SPC coverage layer.
The post-approval infringement scenario: The worst-case scenario for a UK life sciences market entry is a post-approval infringement assertion by an originator patent holder or SPC holder. At this stage, the regulatory investment has been committed, the product is in market, and the commercial pressure to continue selling is at its highest. An interim injunction from the UK courts — which can be obtained relatively quickly in pharmaceutical patent disputes where the claimant can establish a serious issue to be tried and the balance of convenience favours injunctive relief — can halt sales pending a full trial. The parallel FTO management approach prevents this scenario by identifying blocking patents before the MHRA submission commits the regulatory investment.
How to Sequence FTO Relative to the MHRA Pathway
Our guide on when to conduct an FTO search sets out the general timing framework. For UK life sciences products specifically, three FTO checkpoints aligned to MHRA milestones give the most complete protection against post-approval patent risk.
Checkpoint 1: Pre-Submission FTO (12-18 Months Before MHRA Filing) Full FTO analysis covering all UKIPO patents, EPO-validated UK patents, and UK SPCs in the relevant therapeutic category. This checkpoint identifies all blocking patents in the current landscape, enables design-around or formulation decisions before the product configuration is locked for regulatory submission, and provides the IP risk assessment that informs the go/no-go commercial decision on UK market entry. Critically, this is the only checkpoint where design-around options are still commercially viable without triggering a new regulatory submission.
Checkpoint 2: Submission-Stage FTO Update (At or Just Before MHRA Filing) Targeted update covering the 12-18 months since the pre-submission analysis. Focus on: newly granted UK patents from key originators and other active filers in the relevant therapeutic classification, newly published UKIPO applications that may grant before approval, UK SPC applications and grants covering the product or its therapeutic class, and any product configuration changes made during clinical development that alter the FTO scope from the initial analysis.
Checkpoint 3: Pre-Launch Monitoring (Throughout the Approval Period) Continuous patent monitoring covering new UKIPO grants and published applications in the relevant therapeutic patent classifications. Monthly or quarterly monitoring reports reviewed by patent counsel ensure FTO currency throughout the approval period. Any material new patent identified during monitoring triggers a focused clearance analysis before commercial launch — not a full FTO refresh, but a targeted assessment of the specific new right against the approved product.
Patent Categories Specific to UK Life Sciences FTO
UK pharmaceutical compound and formulation patents post-Brexit: EPO-validated UK patents covering pharmaceutical compounds and formulations are the primary blocking patent category for most UK life sciences FTO analyses. Post-Brexit, these patents are governed by the UK Patents Act 1977 and enforced through UK national courts. UK claim construction follows the purposive construction standard established in Kirin-Amgen v Hoechst Marion Roussel and subsequent UK Supreme Court decisions — a standard that has some divergence from the EPO’s approach to claim interpretation in prosecution and is materially different from US claim construction practice. FTO analyses for UK pharmaceutical compound patents must apply UK purposive construction, not EPO or USPTO scope assumptions.
Second medical use patents: the UK approach after Warner-Lambert: Second medical use patents — Swiss-form claims (use of compound X for the manufacture of a medicament for the treatment of condition Y) and purpose-limited product claims (compound X for use in treating condition Y) — are particularly significant in UK life sciences FTO because of the UK Supreme Court’s decision in Warner-Lambert v Generics. The Warner-Lambert decision established how second medical use patent claims are construed and when a generic or biosimilar manufacturer infringes a second medical use patent. For life sciences products entering the UK market where originator second medical use patents are active, the Warner-Lambert framework is a critical analytical input to the FTO claim assessment.
Biologics and biosimilar-specific FTO considerations: Biologic drug FTO in the UK requires coverage of both the primary biologic composition patents and the manufacturing process patents that cover the specific cell line, fermentation process, and purification methodology used to produce the biologic. For biosimilar developers, UK courts have developed specific case law around the interaction between biologic composition patents, manufacturing process patents, and the regulatory data protection periods that run alongside patent protection. A biosimilar FTO that covers only composition patents without covering the manufacturing process patent layer may miss blocking positions that UK originators specifically file to protect their biologic manufacturing advantage.
How Our FTO Service Covers UK Life Sciences Products
Our freedom to operate service covers UK life sciences FTO across all three MHRA-aligned checkpoints: pre-submission full FTO covering UKIPO patents, EPO-validated UK patents, and UK SPCs; submission-stage update with focused coverage of newly granted UK rights; and pre-launch monitoring programme for the approval period. For pharmaceutical compound FTO, we apply UK purposive construction standards and Warner-Lambert second medical use claim analysis. For biologic and biosimilar FTO, we cover manufacturing process patents alongside composition patents. For products with UK SPC exposure, we provide a separate UK SPC register search and SPC validity pre-assessment for blocking SPCs. The output gives life sciences product teams and their UK IP counsel a clearance assessment that reflects the current UK patent and SPC landscape at each MHRA milestone — not a point-in-time analysis that may be stale by the time the product reaches launch.
Navigating MHRA approval for a life sciences product? Patent clearance and regulatory approval must run in parallel. Our service covers all three MHRA-aligned FTO checkpoints with UK purposive construction, SPC coverage, and pre-launch monitoring. → Contact Us
Conclusion: The Takeaway
MHRA approval and patent FTO are independent clearances that must both be complete before a UK life sciences product can be launched commercially. The post-Brexit UK patent landscape — with its independent SPC system, UK purposive construction standard, and separate national enforcement framework — requires UK-specific patent analysis that cannot be derived from EU or US FTO analyses alone.
The three-checkpoint parallel management approach — pre-submission full FTO, submission-stage update, and continuous pre-launch monitoring — keeps the IP clearance current at each MHRA milestone. That is the approach that arrives at commercial launch with both regulatory approval and patent clearance accurate and complete — rather than one current and the other stale from the pre-submission stage.
